...
trda-img

Entrada Therapeutics Inc, Common Stock

TRDA

NMQ

$17.732

-$0.72

(-3.9%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$690.40M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
12.8125
Volume info-icon
This is the total number of shares traded during the most recent trading day.
68.54K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.27
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$11.35 L
$21.79 H
$17.732

About Entrada Therapeutics Inc, Common Stock

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameTRDASectorS&P500
1-Week Return-10.04%-3.39%0.2%
1-Month Return5.73%-1.92%2.72%
3-Month Return30.3%-10.54%7.31%
6-Month Return21.3%-4.47%10.44%
1-Year Return26.89%4.06%27.53%
3-Year Return20.2%0.94%30.88%
5-Year Return-22.96%36.67%89.21%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue---25.26M129.01M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":19.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue104.00K326.00K1.12M1.90M99.88M[{"date":"2019-12-31","value":0.1,"profit":true},{"date":"2020-12-31","value":0.33,"profit":true},{"date":"2021-12-31","value":1.12,"profit":true},{"date":"2022-12-31","value":1.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(104.00K)(326.00K)(1.12M)(1.90M)29.13M[{"date":"2019-12-31","value":-0.36,"profit":false},{"date":"2020-12-31","value":-1.12,"profit":false},{"date":"2021-12-31","value":-3.83,"profit":false},{"date":"2022-12-31","value":-6.51,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(7.50%)22.58%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":-33.23,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses11.82M26.67M51.13M97.25M132.18M[{"date":"2019-12-31","value":8.95,"profit":true},{"date":"2020-12-31","value":20.18,"profit":true},{"date":"2021-12-31","value":38.68,"profit":true},{"date":"2022-12-31","value":73.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(11.82M)(26.67M)(51.13M)(97.25M)(3.16M)[{"date":"2019-12-31","value":-1182400000,"profit":false},{"date":"2020-12-31","value":-2666700000,"profit":false},{"date":"2021-12-31","value":-5112700000,"profit":false},{"date":"2022-12-31","value":-9724800000,"profit":false},{"date":"2023-12-31","value":-316200000,"profit":false}]
Total Non-Operating Income/Expense7.17M288.00K(62.00K)5.26M27.09M[{"date":"2019-12-31","value":26.48,"profit":true},{"date":"2020-12-31","value":1.06,"profit":true},{"date":"2021-12-31","value":-0.23,"profit":false},{"date":"2022-12-31","value":19.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(5.10M)(26.52M)(51.16M)(94.62M)12.06M[{"date":"2019-12-31","value":-42.3,"profit":false},{"date":"2020-12-31","value":-220,"profit":false},{"date":"2021-12-31","value":-424.34,"profit":false},{"date":"2022-12-31","value":-784.8,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes(451.00K)(144.00K)(1.09M)(7.16M)18.74M[{"date":"2019-12-31","value":-2.41,"profit":false},{"date":"2020-12-31","value":-0.77,"profit":false},{"date":"2021-12-31","value":-5.79,"profit":false},{"date":"2022-12-31","value":-38.2,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(4.65M)(26.38M)(50.07M)(87.46M)(6.68M)[{"date":"2019-12-31","value":-464900000,"profit":false},{"date":"2020-12-31","value":-2637900000,"profit":false},{"date":"2021-12-31","value":-5007200000,"profit":false},{"date":"2022-12-31","value":-8745700000,"profit":false},{"date":"2023-12-31","value":-668500000,"profit":false}]
Income From Continuous Operations(5.10M)(26.52M)(51.16M)(94.62M)(21.77M)[{"date":"2019-12-31","value":-510000000,"profit":false},{"date":"2020-12-31","value":-2652300000,"profit":false},{"date":"2021-12-31","value":-5115800000,"profit":false},{"date":"2022-12-31","value":-9461600000,"profit":false},{"date":"2023-12-31","value":-2177000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(4.65M)(26.38M)(50.07M)(87.46M)(6.68M)[{"date":"2019-12-31","value":-464900000,"profit":false},{"date":"2020-12-31","value":-2637900000,"profit":false},{"date":"2021-12-31","value":-5007200000,"profit":false},{"date":"2022-12-31","value":-8745700000,"profit":false},{"date":"2023-12-31","value":-668500000,"profit":false}]
EPS (Diluted)(5.18)(12.26)(18.20)(3.02)(0.26)[{"date":"2019-12-31","value":-518.12,"profit":false},{"date":"2020-12-31","value":-1226.31,"profit":false},{"date":"2021-12-31","value":-1820.19,"profit":false},{"date":"2022-12-31","value":-302,"profit":false},{"date":"2023-12-31","value":-26,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TRDA
Cash Ratio 6.36
Current Ratio 6.59
Quick Ratio 6.64

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TRDA
ROA (LTM) 6.95%
ROE (LTM) 16.42%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TRDA
Debt Ratio Lower is generally better. Negative is bad. 0.24
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TRDA
Trailing PE 12.81
Forward PE 3333.33
P/S (TTM) 3.21
P/B 1.63
Price/FCF NM
EV/R 1.40
EV/Ebitda 4.93

FAQs

What is Entrada Therapeutics Inc share price today?

Entrada Therapeutics Inc (TRDA) share price today is $17.732

Can Indians buy Entrada Therapeutics Inc shares?

Yes, Indians can buy shares of Entrada Therapeutics Inc (TRDA) on Vested. To buy Entrada Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TRDA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Entrada Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Entrada Therapeutics Inc (TRDA) via the Vested app. You can start investing in Entrada Therapeutics Inc (TRDA) with a minimum investment of $1.

How to invest in Entrada Therapeutics Inc shares from India?

You can invest in shares of Entrada Therapeutics Inc (TRDA) via Vested in three simple steps:

  • Click on Sign Up or Invest in TRDA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Entrada Therapeutics Inc shares
What is Entrada Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Entrada Therapeutics Inc (TRDA) is $21.79. The 52-week low price of Entrada Therapeutics Inc (TRDA) is $11.35.

What is Entrada Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Entrada Therapeutics Inc (TRDA) is 12.8125

What is Entrada Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Entrada Therapeutics Inc (TRDA) is 1.63

What is Entrada Therapeutics Inc dividend yield?

The dividend yield of Entrada Therapeutics Inc (TRDA) is 0.00%

What is the Market Cap of Entrada Therapeutics Inc?

The market capitalization of Entrada Therapeutics Inc (TRDA) is $690.40M

What is Entrada Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Entrada Therapeutics Inc is TRDA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top